Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kurt Püchler"'
Autor:
Kurt Püchler, Jörg Rennecke
Publikováno v:
Drug Information Journal. 39:311-319
The number of research projects in Central and Eastern Europe is increasing rapidly but experience with this region remains limited in the global headquarters of many pharmaceutical companies. The outsourcing of project management activities in Centr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc357482885f973616f39d03aeb3c5d1
https://doi.org/10.1177/009286150503900309
https://doi.org/10.1177/009286150503900309
Publikováno v:
Journal of Hypertension. 19:S41-S48
To assess the efficacy and safety of the novel angiotensin II antagonist olmesartan medoxomil in patients with mild to moderate essential hypertension, using a meta-analysis of the combined database from seven US and European clinical trials.Studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d655c7dcdb6b69b90c3c85b2263f4f01
https://doi.org/10.1097/00004872-200106001-00006
https://doi.org/10.1097/00004872-200106001-00006
Publikováno v:
Journal of Hypertension. 19:S21-S32
Orally administered olmesartan medoxomil was rapidly absorbed from the gastrointestinal tract and converted during absorption to olmesartan, the pharmacologically active metabolite that was subsequently excreted without further metabolism. The medoxo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cfabf941b505d6fc818efe256a80521
https://doi.org/10.1097/00004872-200106001-00004
https://doi.org/10.1097/00004872-200106001-00004
Autor:
Kurt Püchler, John C. Alexander
Publikováno v:
Drug Information Journal. 35:599-605
In clinical trials, generally only about half of unselected patients with mild to moderate hypertension respond to treatment with antihypertensive monotherapy. In clinical practice, only about a quarter of hypertensive patients actually achieve the d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a572ad8aa2161d7aea09722e1ee6f9b
https://doi.org/10.1177/009286150103500231
https://doi.org/10.1177/009286150103500231
Publikováno v:
International Clinical Psychopharmacology. 12:S17-S24
Electro-oculogram (including saccadic eye movements), auditory-evoked potentials and visual analogue scales for a subjective impression of effects were used to evaluate some pharmacodynamic properties of RS-8359. In the electro-oculogram, administrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4b39f424364f483247dd8432ce98fff
https://doi.org/10.1097/00004850-199709005-00004
https://doi.org/10.1097/00004850-199709005-00004
Publikováno v:
International Clinical Psychopharmacology. 12:S25-S30
The potential liability of RS-8359 for the 'cheese' effect that is characteristic of the classical monoamine oxidase inhibitors has been compared with placebo and moclobemide in the tyramine test. Both RS-8359 and moclobemide reduce the dose of tyram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa09a5e4be2a575cd207dc61a6c4146e
https://doi.org/10.1097/00004850-199709005-00005
https://doi.org/10.1097/00004850-199709005-00005
Publikováno v:
International Clinical Psychopharmacology. 12:S11-S16
RS-8359 is very rapidly absorbed, metabolized and distributed following oral dosing, with significant concentrations of both parent drug and its principal metabolite appearing in plasma within 15 min. Plasma levels were linearly related to doses of u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53c6e4c535709d765b254fd3757e9e53
https://doi.org/10.1097/00004850-199709005-00003
https://doi.org/10.1097/00004850-199709005-00003
Publikováno v:
Journal of hypertension. 15(12 Pt 2)
Objective This study was conducted to assess the dose-response relationship of the new angiotensin II (Ang II) antagonist CS-866 on blood pressure and on endocrine parameters in hypertensive patients with an activated renin-angiotensin system. Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb86f61801cfef478cb35ae634d4f7af
https://pubmed.ncbi.nlm.nih.gov/9488244
https://pubmed.ncbi.nlm.nih.gov/9488244
Publikováno v:
International clinical psychopharmacology. 12
RS-8359 is a new reversible inhibitor of monoamine oxidase A (RIMA). With a selectivity ratio of about 2200 for the A:B enzyme types, it is one of the most specific of this class of compounds. As a result, it shows relatively little effect upon blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f36b2062e4ebc185bdf00626b186fc
https://pubmed.ncbi.nlm.nih.gov/9466163
https://pubmed.ncbi.nlm.nih.gov/9466163
Publikováno v:
Blood pressure. 6(4)
This 1-year, dose-titration, General Practitioner (GP) study compared efficacy, tolerability and safety of oral temocapril (10-40 mg once daily) with atenolol (25-100 mg once daily) in mild to moderate adult hypertensives (diastolic blood pressure (D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::070eeed237b3b4a0da1ffa8ddf11429a
https://pubmed.ncbi.nlm.nih.gov/9296310
https://pubmed.ncbi.nlm.nih.gov/9296310